ART26.12 is an orally active FABP5 inhibitor with anti-cannabinoid properties. ART26.12 effectively prevents and alleviates Oxaliplatin -induced pain through lipid modulation and cannabinoid receptor activation.
References:
[1]. Warren G, et al. Discovery and Preclinical Evaluation of a Novel Inhibitor of FABP5, ART26.12, Effective in Oxaliplatin-Induced Peripheral Neuropat. J Pain. 2024 Jul;25(7):104470.
















